Browsing by Author "Delgado, Manuel"
Now showing items 1-9 of 9
-
Characterization of chronic HCV infection in Northwest Spain: impact of the treatment strategic plan of the Spanish National Health Service on HCV cure
Grandal, Marta; Pernas, Berta; Mariño, Ana; Álvarez, Hortensia; Tabernilla, Andrés; Castro-Iglesias, Ángeles; Mena, Álvaro; Delgado, Manuel; Pértega-Díaz, Sonia; Poveda, Eva (Wiley, 2017-03-14)[Abstract] The aim of the study was to characterize HCV infection in Northwest Spain and assess the impact of the Spanish Strategic Plan to cure HCV infection. Overall, 387 patients were included (60.9% HIV/HCV coinfected ... -
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Chen, Qian; Perales, Celia; Soria, María Eugenia; García-Cehic, Damir; Gregori, Josep; Rodríguez-Frías, Francisco; Buti, M.; Crespo, Javier; Calleja, J.L.; Tabernero, David; Vila Salvador, Marta; Lázaro, Fernando; Rando-Segura, Ariadna; Nieto-Aponte, Leonardo; Llorens-Revull, Meritxell; Cortese, Maria Francesca; Fernández, Irati; Castellote, José; Niubó, Jordi; Imaz, Arkaitz; Delgado, Manuel; Cañizares, Angelina; Castro-Iglesias, Ángeles (Elsevier, 2019-12-16)[Abstract] A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-based treatment regimens, often because of drug resistance-associated substitutions (RAS). The aim of this study was ... -
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients: results in real clinical practice
Margusino-Framiñán, Luis; Cid-Silva, Purificación; Mena, Álvaro; Rodríguez-Osorio, Iria; Pernas, Berta; Delgado, Manuel; Pértega-Díaz, Sonia; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles (Sociedad Española de Quimioterapia, 2019)[Abstract] OBJECTIVE: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this ... -
Effectiveness and safety of direct‐acting antivirals in hepatitis C infected patients with mental disorders: results in real clinical practice
Bobadilla-Pérez, Eva; Cid-Silva, Purificación; Rodríguez‐Sotelo, Alejandro; Yáñez‐Rubal, Juan C.; Mena, Álvaro; Suárez-López, Francisco; Prieto‐Pérez, Andrea; Giménez‐Arufe, Víctor; Delgado, Manuel; Sanclaudio‐Luhia, Ana I.; Martín‐Herranz, Isabel; Castro-Iglesias, Ángeles; Margusino-Framiñán, Luis (Willey Online Library, 2020-03-17)[Abstract] The aim of this study is to analyze the effectiveness and safety of direct‐acting antivirals (DAAs) in psychiatric patients with chronic hepatitis C (CHC). Secondary objectives included adherence and drug‐drug ... -
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients
Margusino-Framiñán, Luis; Cid-Silva, Purificación; Rotea-Salvo, Sandra; Mena, Álvaro; Suárez-López, Francisco; Vázquez-Rodríguez, Pilar; Delgado, Manuel; Sanclaudio-Luhia, Ana I.; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles (BMJ Publishing Group, 2020-02-07)[Abstract] Objectives. Sofosbuvir/velpatasvir±ribavirin (SOF/VEL±RBV) and glecaprevir/pibrentasvir (GLE/PIB) are the drug combinations of choice for treating individuals with genotype 3 hepatitis C virus (G3-HCV) infection. ... -
Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals
Rodríguez-Osorio, Iria; Mena, Álvaro; Meijide, Héctor; Morano, Luis; Delgado, Manuel; Cid-Silva, Purificación; Margusino-Framiñán, Luis; Pedreira, José D.; Castro-Iglesias, Ángeles (Plos ONE, 2019-06-03)[Abstract] BACKGROUND: Direct-acting antivirals (DAAs) are effective in patients aged ≥65 years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular ... -
Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies
Grandal, Marta; Pernas, Berta; Tabernilla, Andrés; Mariño, Ana; Álvarez, Hortensia; Valcarce, Nieves; Mena, Álvaro; Castro-Iglesias, Ángeles; Pérez, Ana B.; Delgado, Manuel; Poveda, Eva (Wiley, 2018-02-10)[Abstract] The presence of resistance‐associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs). HCV resistance at NS5A region is mainly focused on patients with ... -
Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients
Rodríguez-Osorio, Iria; Cid-Silva, Purificación; Morano, Luis; Castro-Iglesias, Ángeles; Suárez, Marta; Delgado, Manuel; Margusino-Framiñán, Luis; Meijide, Héctor; Pernas, Berta; Tabernilla, Andrés; Pedreira, José D.; Mena, Álvaro; Poveda, Eva (Elsevier, 2017-01-18)[Abstract] Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated. Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have ... -
Seroprevalence of HCV and HIV infections by year of birth in Spain: impact of US CDC and USPSTF recommendations for HCV and HIV testing
Mena, Álvaro; Moldes, Luz; Meijide, Héctor; Cañizares, Angelina; Castro-Iglesias, Ángeles; Delgado, Manuel; Pértega-Díaz, Sonia; Pedreira, José D.; Bou, Germán; Poveda, Eva (PLoS ONE, 2014-12-01)
